Sorrento Therapeutics is making strides in its development of new treatments for cancer, inflammation, and autoimmune diseases. The California-based biopharmaceutical company is focused on antibodies, with multiple late-stage biosimilar and biobetter antibody products, as well as clinical CAR-T therapies targeting solid tumors, in its pipeline. With a broad foundation in antibody research and development, Sorrento is poised to be a strong contender in the biopharmaceutical market.
Sorrento Therapeutics's ticker is SRNE
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Sorrento Therapeutics
It is http://sorrentotherapeutics.com/
Sorrento Therapeutics is in the Healthcare sector
Sorrento Therapeutics is in the Biotechnology industry
The following five companies are Sorrento Therapeutics's industry peers: